Beta Bio: 3 Key Takeaways for Long-Term Investors
Beta Bionics Announces Participation at Upcoming Investor Conferences
TD Cowen Maintains Hold on Beta Bionics, Raises Price Target to $21
Beta Bionics, Inc. Q3 2026 Earnings Call Summary
Piper Sandler Reiterates Overweight on Beta Bionics, Raises Price Target to $24
Beta Bionics, Inc. 2026 Q3 - Results - Earnings Call Presentation
Beta Bionics (BBNX) Q3 2026 Earnings Call Transcript
Beta Bionics Q3 Earnings Call Highlights
Beta Bionics, Inc. (BBNX) Q3 2026 Earnings Call Transcript
Beta Bionics (NASDAQ:BBNX) Slides After Q3 Results as Guidance and Product Timing Weigh
Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates
Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
Beta Bionics Q3 2026 Earnings Call Transcript
Beta Bionics Raises FY2026 Sales Guidance from $121.000M-$126.000M to $124.000M-$126.000M vs $126.626M Est
Beta Bionics Q3 EPS $(0.52) Beats $(0.53) Estimate, Sales $35.505M Beat $34.722M Estimate
Beta Bionics, Inc. (BBNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Jefferies Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $30
Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026
Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $28
Wells Fargo Initiates Coverage On Beta Bionics with Overweight Rating, Announces Price Target of $28
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.